Clarus Ventures has led a $35.7 million first round for Canada's Variation Biotechnologies. The biotech company's lead candidate is a new vaccine for influenza. ARCH Venture Partners and 5AM Ventures also took part in the round.
- here's the release on the venture round
ALSO: Horizon Therapeutics has raised an additional $15 million through a Series B financing to advance its lead product HZT-501, a "GI-friendly" prescription NSAID, into pivotal Phase III clinical trials in the first half of this year. Scale Venture Partners, formerly known as BA Venture Partners, led the round with Sutter Hill Ventures and Pequot Ventures also participating. Horizon completed a $6 million Series A round in October 2005 with the same syndicate of investors. Release